Morgan Stanley analyst Michael Ulz raised the firm’s price target on Silence Therapeutics to $49 from $45 and keeps an Overweight rating on the shares. Initial Phase 1 data for divesrian in polycythemia vera PV were better-than-expected, with the near elimination of phlebotomies in a broad population, and justify moving rapidly into a Phase 2 study by year-end and further validate the platform, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLN:
- Silence Therapeutics’ Divesiran Shows Promise in PV Study
- Silence Therapeutics Secures $2M Milestone Payment
- Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma
- Silence Therapeutics’ Zerlasiran Shows Promising Results
- Silence Therapeutics announces 48-week data from Phase 2 study of zerlasiran